ALGS: חוב לטווח קצר של החברה Aligos Therapeutics Inc.

Aligos Therapeutics (ALGS) is currently in the clinical testing stage, where research expenses generate a constant cash outflow. The company's short-term borrowings confirm this burden, while 0.00 reflects the baseline level of the metric. While trial failure risks and competition pose threats, high R&D costs and patents protect the business from new entrants.

This metric assesses the ratio of current borrowings to working capital, determining the balance between the issuer's solvency and investment potential. For Aligos Therapeutics (ALGS), which is developing liver therapies through strategic alliances, credit obligations under one year reflect the ability to fund clinical trials without default risk, confirming the high reliability of the company's asset structure.